Market Overview

Antibe Therapeutics Reports 2017 Year-End Financial and Operating Results

Share:

Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQX:ATBPF) filed its
financial and operating results Friday, July 28 for the fourth quarter
and the year ended March 31, 2017. The Corporation's audited 2017
financial statements, MD&A and AIF are available on SEDAR.

About Antibe Therapeutics Inc.

Antibe develops safer medicines for pain and inflammation. Antibe's
technology involves linking a hydrogen sulfide-releasing molecule to an
existing drug to produce a patented, improved medicine. Antibe's lead
drug ATB-346 targets the global need for a safer, non-addictive drug for
chronic pain and inflammation. ATB-352, the second drug in Antibe's
pipeline, targets the urgent global need for a safer, non-addictive
analgesic for treating severe acute pain, while ATB-340 is a GI-safe
derivative of aspirin. www.antibethera.com.

Antibe's subsidiary, Citagenix Inc. ("Citagenix"), is a leader in the
sales and marketing of tissue regenerative products servicing the
orthopedic and dental marketplaces. Since its inception in 1997,
Citagenix has become an important source of knowledge and experience in
the Canadian medical device industry. Citagenix Inc. is active in 15
countries, operating in Canada through its direct sales teams, and
internationally via a network of distributor partnerships. www.citagenix.com.

Forward Looking Information

This news release includes certain forward-looking statements, which may
include, but are not limited to, the completion of financing
transactions and the licensing and development of drugs and medical
devices. Any statements contained herein that are not statements of
historical facts may be deemed to be forward-looking, including those
identified by the expressions "will", "anticipate", "believe", "plan",
"estimate", "expect", "intend", "propose" and similar expressions.
Forward-looking statements involve known and unknown risks and
uncertainties that could cause actual results, performance, or
achievements to differ materially from those expressed or implied in
this news release. Factors that could cause actual results to differ
materially from those anticipated in this news release include, but are
not limited to, failure to raise the full Offering amount, failure to
obtain TSX Venture Exchange approval for the transactions described
herein, and risks associated with drug and medical device development
generally. Antibe Therapeutics Inc. assumes no obligation to update the
forward-looking statements or to update the reasons why actual results
could differ from those reflected in the forward-looking statements
except as required by applicable law.

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com